Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  


Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare

Cellecta  

Charles River Discovery

Elsevier 

 NanoString     

 SeraCare 

Silicon Biosystems   

 Streck 

 TriMetis


XIFIN

  View All Sponsors 


Cambridge Healthtech Institute’s Fourth Annual

Circulating Cell-Free DNA

Overcoming Technical Challenges to Provide Clinical Solutions

February 23-24, 2017 | Moscone South Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference

 

The development of noninvasive methods to detect and monitor tumors continues to be a bottleneck in oncology research. Circulating cell-free DNA shows great promise, but still requires improvements and additional research before it becomes standard practice. At Cambridge Healthtech Institute’s Fourth Annual Circulating Cell-Free DNA, leading researchers from academia and industry will come together to address advances as well as existing challenges in this rapidly growing field. This year’s event will place emphasis on early detection, monitoring treatment response, and moving cfDNA into clinical practice.

Who should attend: Vice Presidents, Directors, Managers, CEOs, CSOs, Professors and Scientists from Large Pharma, Biotechs and Academia working in fields such as molecular oncology, cancer biomarkers, molecular diagnostics, translational research, genetics, and research and development.

Topics may include, but are not limited to:

  • Achieving early detection
    • Biological and technical limitations
    • Increasing sensitivity and specificity
    • Establishing standards
    • What and when to screen

  • Complementary approaches including:
    • RNA
    • miRNA
    • Exosomes


 
  • Monitoring treatment response in different therapies such as chemo- and immunotherapies
  • Detecting resistance mutations
  • Moving cfDNA into clinical practice:
    • Research perspective
    • Clinician perspective
    • Regulator perspective

  • Using cfDNA in pharma clinical trials
  • Reimbursement of tests
  • Epigenetic markers of cfDNA

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is July 25, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Samantha Drinkwater
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5461
E: sdrinkwater@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com